{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:05:47Z","timestamp":1789733147766,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013342","name":"National Institute for Health Research Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.waojou.2026.101449","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T07:02:05Z","timestamp":1787122925000},"page":"101449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and cost implications of broadening asthma biologic eligibility criteria"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2858-1559","authenticated-orcid":false,"given":"Freda","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grainne","family":"d\u2019Ancona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe I.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.waojou.2026.101449_bib1","series-title":"The Global Asthma Report","year":"2022"},{"issue":"11","key":"10.1016\/j.waojou.2026.101449_bib2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMcp2304871","article-title":"Asthma in adults","volume":"389","author":"Mosnaim","year":"2023","journal-title":"N Engl J Med"},{"issue":"175","key":"10.1016\/j.waojou.2026.101449_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0088-2024","article-title":"Biologics in severe asthma: a state-of-the-art review","volume":"34","author":"Gyawali","year":"2025","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.waojou.2026.101449_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.12.027","article-title":"Global variability in administrative approval prescription criteria for biologic therapy in severe asthma","author":"Porsbjerg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.waojou.2026.101449_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2020.100502","article-title":"Biologics and global burden of asthma: a worldwide portrait and a call for action","volume":"14","author":"Caminati","year":"2021","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.waojou.2026.101449_bib6","series-title":"Overview | Tezepelumab for Treating Severe Asthma | Guidance | NICE","year":"2023"},{"key":"10.1016\/j.waojou.2026.101449_bib7","unstructured":"National Institute for Health and Care Excellence (NICE). Benralizumab for Treating Severe Eosinophilic Asthma [Internet]. Available from: https:\/\/www.nice.org.uk\/guidance\/TA565\/chapter\/1-Recommendations."},{"key":"10.1016\/j.waojou.2026.101449_bib8","unstructured":"National Institute for Health and Care Excellence (NICE). Mepolizumab for Treating Severe Eosinophilic Asthma [Internet]. Available from: https:\/\/www.nice.org.uk\/guidance\/TA671\/chapter\/1-Recommendations."},{"key":"10.1016\/j.waojou.2026.101449_bib9","unstructured":"National Institute for Health and Care Excellence (NICE). Dupilumab for Treating Severe Asthma with Type 2 Inflammation [Internet]. Available from: https:\/\/www.nice.org.uk\/guidance\/TA751\/chapter\/1-Recommendations."},{"issue":"12","key":"10.1016\/j.waojou.2026.101449_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101155","article-title":"Global prevalence of eligibility for biologic therapy in ATS\/ERS-defined severe asthma: a systematic review","volume":"18","author":"Yang","year":"2025","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.waojou.2026.101449_bib11","article-title":"Clinical response and remission in severe asthma patients treated with biologic therapies","author":"Hansen","year":"2023","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.waojou.2026.101449_bib12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.waojou.2026.101449_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01497-2024","article-title":"Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma","volume":"65","author":"Soendergaard","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.waojou.2026.101449_bib14","first-page":"15","article-title":"Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial","author":"Ghanei","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.waojou.2026.101449_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/1750743X.2025.2467026","article-title":"Pharmacokinetics and safety of CT-P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe","volume":"17","author":"Hasunuma","year":"2025","journal-title":"Immunotherapy"},{"key":"10.1016\/j.waojou.2026.101449_bib16","series-title":"Omlyclo | European Medicines Agency (EMA)","year":"2024"},{"issue":"8","key":"10.1016\/j.waojou.2026.101449_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017474","article-title":"Validation of asthma recording in the Clinical Practice Research Datalink (CPRD)","volume":"7","author":"Nissen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.waojou.2026.101449_bib18","series-title":"Overview | Asthma: Diagnosis, Monitoring and Chronic Asthma Management (BTS, NICE, SIGN) | Guidance | NICE","year":"2024"},{"key":"10.1016\/j.waojou.2026.101449_bib19","unstructured":"2024 GINA Main Report. Global Initiative for Asthma - GINA [Internet]. [cited 2025 Aug 22]. Available from: https:\/\/ginasthma.org\/2024-report\/."},{"issue":"1","key":"10.1016\/j.waojou.2026.101449_bib20","article-title":"Pre-biologic assessment of adherence in severe asthma and association with biologic continuation: a UK Severe Asthma Registry Study","volume":"12","author":"Yang","year":"2025","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.waojou.2026.101449_bib21","unstructured":"The King\u2019s Fund [Internet]. [cited 2025 Sep 19]. NHS: Key Facts and Figures. Available from: https:\/\/www.kingsfund.org.uk\/insight-and-analysis\/data-and-charts\/key-facts-figures-nhs."},{"issue":"10","key":"10.1016\/j.waojou.2026.101449_bib22","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A Study: Real-World oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.waojou.2026.101449_bib23","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1007\/s12325-025-03231-6","article-title":"Effectiveness and safety of tezepelumab in a diverse population of US patients with severe asthma: initial results of the PASSAGE Study","volume":"42","author":"Lugogo","year":"2025","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.waojou.2026.101449_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12931-023-02539-7","article-title":"Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study","volume":"24","author":"Padilla-Galo","year":"2023","journal-title":"Respir Res"},{"issue":"11","key":"10.1016\/j.waojou.2026.101449_bib25","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1007\/s12325-024-02967-x","article-title":"Real-World effectiveness of mepolizumab in severe asthma: results from the multi-country, self-controlled nucala effectiveness Study (NEST)","volume":"41","author":"Al-Lehebi","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.waojou.2026.101449_bib26","series-title":"Airway Pharmacology and Treatment [Internet]","article-title":"Severe asthma biologics use in England: a need to increase use and reduce inequity","author":"Rupani","year":"2024"},{"key":"10.1016\/j.waojou.2026.101449_bib27","unstructured":"Health Research Authrity [Internet]. [cited 2025 Aug 22]. RECOGNISE V4.0. Available from: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/research-summaries\/recognise-v40\/."},{"key":"10.1016\/j.waojou.2026.101449_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107170","article-title":"Patient characteristics and eligibility for biologics in severe asthma: results from the Greek cohort of the RECOGNISE \u201creal world\u201d study","volume":"210","author":"Bakakos","year":"2023","journal-title":"Respir Med"},{"issue":"suppl 65","key":"10.1016\/j.waojou.2026.101449_bib29","first-page":"PA3729","article-title":"Real-world patient characteristics and eligibility for biologics in severe asthma (RECOGNISE)","volume":"58","author":"Kanniess","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.waojou.2026.101449_bib30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jaip.2018.05.032","article-title":"Prevalence of patients eligible for Anti-IL-5 treatment in a cohort of adult-onset asthma","volume":"7","author":"Ilmarinen","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2026.101449_bib31","article-title":"Severe asthma in the US population and eligibility for monoclonal antibody therapy","author":"Akenroye","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.waojou.2026.101449_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.rmed.2013.10.026","article-title":"Eligibility for treatment with omalizumab in Italy and Germany","volume":"108","author":"Buhl","year":"2014","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.waojou.2026.101449_bib33","first-page":"152","article-title":"Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study","volume":"55","author":"Albers","year":"2018","journal-title":"J Asthma Off J Assoc Care Asthma"},{"issue":"4","key":"10.1016\/j.waojou.2026.101449_bib34","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01836-2017","article-title":"Nonadherence in the era of severe asthma biologics and thermoplasty","volume":"51","author":"Lee","year":"2018","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.waojou.2026.101449_bib35","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3390\/jcm12041546","article-title":"Baseline characteristics of patients enrolled in clinical trials of biologics for severe asthma as potential predictors of outcomes","volume":"12","author":"Menzella","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.waojou.2026.101449_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13223-018-0301-6","article-title":"Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective","volume":"14","author":"Jeimy","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"10.1016\/j.waojou.2026.101449_bib37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jaip.2014.05.005","article-title":"The prevalence of severe asthma and low asthma control among Danish adults","volume":"2","author":"von B\u00fclow","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2026.101449_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105919","article-title":"Multinational cohort study of mortality in patients with asthma and severe asthma","volume":"165","author":"Engelkes","year":"2020","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.waojou.2026.101449_bib39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12890-021-01578-4","article-title":"Risk factors for severe adult-onset asthma: a multi-factor approach","volume":"21","author":"Toppila-Salmi","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.waojou.2026.101449_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02332-w","article-title":"Risk factors for the development of bronchiectasis in patients with asthma","volume":"11","author":"Ma","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.waojou.2026.101449_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/JAA.S196200","article-title":"Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab","volume":"12","author":"Carpagnano","year":"2019","journal-title":"J Asthma Allergy"},{"issue":"1","key":"10.1016\/j.waojou.2026.101449_bib42","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12890-023-02786-w","article-title":"Factors influencing poor response to type 2 targeted therapies in severe asthma: a retrospective cohort study","volume":"23","author":"Al-Ahmad","year":"2023","journal-title":"BMC Pulm Med"},{"issue":"4","key":"10.1016\/j.waojou.2026.101449_bib43","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00044-2025","article-title":"Who really responds to asthma biologics? The clue lies in the journey before treatment","volume":"65","author":"Yang","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.waojou.2026.101449_bib44","doi-asserted-by":"crossref","unstructured":"Yang F, Seo S, Hasegawa T, Bloom CI, Zounemat-Kermani N, Bhavsar PK, et al. Longer asthma duration is associated with elevated Non-T2 sputum biomarkers and reduced T2 inflammation in severe asthma. Allergy. n\/a(n\/a). doi:10.1111\/all.70436.","DOI":"10.1111\/all.70436"},{"key":"10.1016\/j.waojou.2026.101449_bib45","unstructured":"Asthma. ICER [Internet]. [cited 2025 Aug 22]. Available from: https:\/\/icer.org\/assessment\/asthma-2018\/."},{"issue":"1","key":"10.1016\/j.waojou.2026.101449_bib46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2017.03.034","article-title":"Clinical predictors of remission and persistence of adult-onset asthma","volume":"141","author":"Westerhof","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.waojou.2026.101449_bib47","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/thoraxjnl-2020-215168","article-title":"Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era","volume":"76","author":"Jackson","year":"2021","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.waojou.2026.101449_bib48","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.jaip.2025.03.011","article-title":"Concurrent blood eosinophils and FeNO as biological therapy indicators in severe asthma: findings from the precision medicine intervention in severe asthma Study","volume":"13","author":"Pham","year":"2025","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455126002826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455126002826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:41:01Z","timestamp":1789731661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455126002826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1939455126002826"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2026.101449","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and cost implications of broadening asthma biologic eligibility criteria","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2026.101449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"101449"}}